cvs health glp-1 receptor agonists weight management diabetes treatments Caremark is adding Zepbound, Eli Lilly's obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk's Wegovy. MORE MinuteClinic Weight-Loss Program expands access
Description
weight or CV risk), with patient preferences and characteristics [62]

There were 632 participants with T2DM and insufficient glycemic controldefined as an A1C between 7.0% and 9.5%despite lifestyle interventions alone or treatment with a stable dose of metformin

doi: 10.4103/picr.PICR_81_17 [DOI] [PMC free article] [PubMed] [Google Scholar] 138.Hamilton RA, Briceland LL, Andritz MH

This effect can be specifically blocked by the GLP-1R antagonist exendin (939) amide

[DOI] [PMC free article] [PubMed] [Google Scholar] 47.Tomovic K., Lazarevic J., Kocic G., Deljanin-Ilic M., Anderluh M., Smelcerovic A
(Reporting by Andrew Silver